Results 1 to 10 of about 117,631 (302)

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations [PDF]

Haematologica, 2014
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics, Tunde Krahling, Katalin Balassa, Gabriella Halm, Andras Bors, Magdalena Koszarska, Arpad Batai, Janos Dolgos, Judit Csomor, Miklos Egyed, Andrea Sipos, Peter Remenyi, Attila Tordai, Tamas Masszi   +13 more
doaj   +3 more sources

Itch and Janus Kinase Inhibitors

Acta Dermato-Venereologica, 2023
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han, Yu Ri Woo, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim   +4 more
doaj   +3 more sources

Structural basis of Janus kinase trans-activation

Cell Reports, 2023
Summary: Janus kinases (JAKs) mediate signal transduction downstream of cytokine receptors. Cytokine-dependent dimerization is conveyed across the cell membrane to drive JAK dimerization, trans-phosphorylation, and activation.
Nathanael A. Caveney, Robert A. Saxton, Deepa Waghray, Caleb R. Glassman, Naotaka Tsutsumi, Stevan R. Hubbard, K. Christopher Garcia   +6 more
doaj   +3 more sources

Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis [PDF]

Open Medicine
This meta-analysis evaluates Janus Kinase (JAK) inhibitors’ efficacy and safety in large vessel vasculitis (LVV), encompassing Giant Cell Arteritis (GCA) and Takayasu’s Arteritis (TAK).
Bai Yang, Wang Zhe, Zhang Chunling
doaj   +2 more sources

Janus kinase inhibitors - their current applications and future prospects [PDF]

Farmacja Polska, 2022
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska, Karolina Żurawska, Maciej Arciszewski, Arnold Kukowka, Bolesław Banach   +4 more
doaj   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana, De Schepper, Sofie, Desmet, Eline, Lambert, Jo, Speeckaert, Reinhart, Van Gele, Mireille   +5 more
core   +12 more sources

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs

Molecular & Cellular Oncology, 2021
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder, Florian Perner, Florian H. Heidel   +2 more
doaj   +1 more source

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment

Immunological Medicine, 2023
Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

Janus Kinase Inhibitors in the Treatment of Alopecia Areata

Prague Medical Report, 2023
Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities
Athanasios J. Stefanis
doaj   +1 more source